Literature DB >> 7896005

Role of the beta-amyloid protein in Alzheimer's disease.

S S Sisodia1, D L Price.   

Abstract

A major histopathological hallmark of Alzheimer's disease (AD) is the presence of amyloid deposits in the parenchyma of the amygdala, hippocampus, and neocortex. The principal component of amyloid is the beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP). APP occurs as several A beta-containing isoforms of 695, 751, and 770 amino acids, with the latter two APP containing a domain that shares structural and functional homologies with Kunitz serine protease inhibitors. In cultured cells, APP mature through the constitutive secretory pathway, and some cell surface-bound APP are cleaved by an enzyme, designated as alpha-secretase, within the A beta domain, an event that precludes A beta amyloidogenesis. Several studies have delineated two additional pathways of APP processing: first, an endosomal/lysosomal pathway generates a complex set of APP-related membrane-bound fragments, some of which contain the entire A beta sequence; and, second, by mechanisms which are not fully understood, A beta 1-40 is secreted into the conditioned medium in vitro and is present in cerebrospinal fluid in vivo. The intracellular sites of enzymes responsible for proteolytic cleavage at the NH2 and COOH termini of A beta, termed gamma- and beta-secretase, respectively, have not been identified. Finally, recent molecular genetic investigations have identified a variety of mutations in APP that segregate with early-onset familial AD and with hereditary cerebral hemorrhage with amyloid, Dutch type (HCHWA-D). Several of these mutations appear to influence APP processing and result in the production of higher levels or longer A beta-related peptides that are inherently more fibrillogenic. Although a variety of lines of evidence implicates APP/A beta in AD, the mechanisms by which A beta influences the biology and vulnerability of neural cells are not fully understood but are very active areas of investigation. This review focuses on the present state of our understanding of APP and A beta in the context of AD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7896005     DOI: 10.1096/fasebj.9.5.7896005

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  62 in total

1.  Distribution of cystine/glutamate exchange transporter, system x(c)-, in the mouse brain.

Authors:  Hideyo Sato; Michiko Tamba; Suzuka Okuno; Kanako Sato; Kazuko Keino-Masu; Masayuki Masu; Shiro Bannai
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 2.  Actin dynamics and cofilin-actin rods in alzheimer disease.

Authors:  James R Bamburg; Barbara W Bernstein
Journal:  Cytoskeleton (Hoboken)       Date:  2016-03-01

3.  Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody.

Authors:  Markus Mandler; Edward Rockenstein; Kiren Ubhi; Lawrence Hansen; Anthony Adame; Sarah Michael; Douglas Galasko; Radmila Santic; Frank Mattner; Eliezer Masliah
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  Interaction of prion protein with small highly structured RNAs: detection and characterization of PrP-oligomers.

Authors:  Sara Vasan; Phyllus Y Mong; Abraham Grossman
Journal:  Neurochem Res       Date:  2006-06-02       Impact factor: 3.996

5.  The Research on the Relationship of RAGE, LRP-1, and Aβ Accumulation in the Hippocampus, Prefrontal Lobe, and Amygdala of STZ-Induced Diabetic Rats.

Authors:  Lou-Yan Ma; Yu-Lang Fei; Xiao-Ye Wang; Song-Di Wu; Jun-Hui Du; Mei Zhu; Long Jin; Ming Li; Hai-Long Li; Jia-Jia Zhai; Lu-Peng Ji; Ran-Ran Ma; Song-Fang Liu; Mo Li; Li Ma; Xiao-Rui Ma; Qiu-Min Qu; Ya-Li Lv
Journal:  J Mol Neurosci       Date:  2017-04-11       Impact factor: 3.444

6.  Recent advances in the development of immunotherapies for tauopathies.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  Exp Neurol       Date:  2010-10-21       Impact factor: 5.330

Review 7.  Nuclear receptors as therapeutic targets for Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  Expert Opin Ther Targets       Date:  2011-07-01       Impact factor: 6.902

8.  From differentiation to proliferation: the secretory amyloid precursor protein as a local mediator of growth in thyroid epithelial cells.

Authors:  C U Pietrzik; J Hoffmann; K Stöber; C Y Chen; C Bauer; D A Otero; J M Roch; V Herzog
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

Review 9.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

10.  Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice.

Authors:  Bingqian Liu; Suhail Rasool; Zhikuan Yang; Charles G Glabe; Steven S Schreiber; Jian Ge; Zhiqun Tan
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.